Loading...

APC/Cyanine7 anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6dot7_APCCyanine7_CD8_Antibody_013019_updated.png
C57BL/6 mouse splenocytes were stained with CD3 FITC and CD8 (clone 53-6.7) APC/Cyanine7 (left) or Rat IgG2a, ? APC/Cyanine7 isotype control (right).
  • 53-6dot7_APCCyanine7_CD8_Antibody_013019_updated.png
    C57BL/6 mouse splenocytes were stained with CD3 FITC and CD8 (clone 53-6.7) APC/Cyanine7 (left) or Rat IgG2a, ? APC/Cyanine7 isotype control (right).
Compare all formats See APC/Cyanine7 spectral data
Cat # Size Price Quantity Check Availability Save
100713 25 µg 76€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100714 100 µg 172€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is =1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Additional Product Notes
BioLegend is in the process of converting the name APC/Cy7 to APC/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our APC/Cyanine7 products. Please contact Technical Service if you have any questions.
Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Kastenmüller K, et al. 2013. Infect Immun . 81:789. PubMed
  2. Quinn K, et al. 2013. J Immunol. 191:5085. PubMed
  3. Chuang H, et al. 2014. Nat Commun. 5:4602. PubMed
  4. Cabrera-Mora M, et al. 2016. J Immunol. 197: 2748 - 2761. PubMed
  5. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  6. Cha JH et al. 2018. Molecular cell. 71(4):606-620 . PubMed
  7. Miragaia RJ, et al. 2019. Immunity. 50:493. PubMed
  8. Chan LC, et al. 2019. J Clin Invest. 129:3324. PubMed
  9. Vono M, et al. 2020. Cell Reports. 28(7):1773-1784.e5.. PubMed
  10. Ajith A, et al. 2021. Front Immunol. 12:687715. PubMed
  11. Apte SH, et al. 2020. Clin Transl Immunology. 9:e1209. PubMed
  12. Berube A, et al. 2022. Viruses. 14:. PubMed
  13. Kaczanowska S, et al. 2021. Cell. 184(8):2033-2052.e21. PubMed
  14. Hirako I, et al. 2016. Nat Commun. 7:13277. PubMed
  15. Singhal A, et al. 2014. Sci Transl Med. 6:263. PubMed
  16. Chen J, et al. 2008. Blood. 111:5163. PubMed
  17. Fu Z, et al. 2019. Cell Rep. 28:159. PubMed
  18. Hastings AK, et al. 2019. iScience. 13:339. PubMed
  19. Romain Bouziat et al. 2018. Cell host & microbe. 24(5):677-688 . PubMed
  20. Hong M, et al. 2021. Int J Mol Sci. 22:. PubMed
  21. Qi Z, et al. 2022. Nat Commun. 13:182. PubMed
  22. Spranger S, et al. 2013. Sci Transl Med. 26:200. PubMed
  23. Sanchez-Felipe L, et al. 2021. Nature. 590:320. PubMed
  24. Turner JS et al. 2018. Cell reports. 25(6):1395-1403 . PubMed
  25. Zhang P et al. 2019. Cell Rep. 27(11):3117-3123 . PubMed
  26. Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed
  27. Wei H, et al. 2021. Malar J. 20:89. PubMed
  28. Rodriguez-García A, et al. 2021. Nat Commun. 12:877. PubMed
  29. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  30. Park JH, et al. 2022. STAR Protoc. 3:101607. PubMed
  31. Hirano KI, et al. 2021. eLife. 0.416666666666667. PubMed
  32. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  33. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
  34. Clement M, et al. 2016. PLoS Pathog. 12:e1006050. PubMed
  35. Zhou Y, et al. 2016. Acta Pharmacol Sin. 10.1038/aps.2016.102. PubMed
  36. Oyarce C, et al. 2018. Front Immunol. 8:1794. PubMed
  37. Jazowiecka-Rakus J, et al. 2021. Cancers (Basel). 13:. PubMed
  38. Liang Y, et al. 2020. J Immunol. 204:2984. PubMed
  39. Rao E, et al. 2021. Sci Immunol. 6:. PubMed
  40. He C, et al. 2020. Clin Transl Med. 10:e39. PubMed
  41. Isakova-Sivak I, et al. 2020. Vaccines (Basel). 8:00. PubMed
  42. Jtte BB, et al. 2021. iScience. 24(8):102833. PubMed
  43. Lian G et al. 2018. eLife. 7 pii: e36158. PubMed
  44. Das S, et al. 2019. Oncogene. 383316. PubMed
  45. Wei SC, et al. 2019. Immunity. 50:1084. PubMed
  46. Guo X, et al. 2020. Nat Commun. 11:2177. PubMed
  47. Somerville TD, et al. 2020. eLife. 9:e53381.. PubMed
  48. Porsche CE, et al. 2021. JCI Insight. 6:. PubMed
  49. Joseph R, et al. 2021. Br J Cancer. 125:176. PubMed
  50. Inoue D, et al. 2021. Nat Genet. 53:707. PubMed
  51. Almshayakhchi R, et al. 2021. Front Oncol. 11:636977. PubMed
  52. Konrath KM, et al. 2022. Cell Rep. 38:110318. PubMed
  53. Enriquez AB, et al. 2022. iScience. 25:104305. PubMed
  54. Sugimoto C, et al. 2022. Elife. 11:. PubMed
  55. Yu AI, et al. 2020. Cell Rep. 107471:31. PubMed
  56. Marangoni F, et al. 2021. Cell. . PubMed
  57. Kitano M, et al. 2016. Proc Natl Acad Sci U S A. 113: 1044 - 1049. PubMed
  58. Ni P, et al. 2014. J Immunol . 193:1778. PubMed
  59. Hsu JM, et al. 2018. Nat Commun. 9:1908. PubMed
  60. Zhang X, et al. 2022. Cell Mol Gastroenterol Hepatol. 14:494. PubMed
  61. Zhang C, et al. 2021. Clin Transl Immunology. 10:e1310. PubMed
  62. Nagarajan D, et al. 2021. Immunol Cell Biol. 99:972. PubMed
  63. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  64. Jassinskaja M, et al. 2021. Cell Reports. 34(12):108894. PubMed
  65. Trotta E, et al. 2018. Nat Med. 24:1005. PubMed
  66. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
  67. Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
  68. Hiltensperger M, et al. 2021. Nat Immunol. 22:880. PubMed
  69. Enriquez AB, et al. 2022. iScience. 25:104305. PubMed
  70. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  71. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  72. Park HB, et al. 2020. Oncoimmunology. 9:1772663. PubMed
  73. Domingos-Pereira S, et al. 2019. Cancer Immunol Res. 7:621. PubMed
  74. Leonard JD et al. 2017. Immunity. 47(1):107-117 . PubMed
  75. Miska J et al. 2019. Cell reports. 27(1):226-237 . PubMed
  76. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  77. Kang SJ, et al. 2022. Food Sci Anim Resour. 42:903. PubMed
  78. Muñoz NM, et al. 2022. Sci Rep. 12:14449. PubMed
  79. Li J, et al. 2021. Cell Commun Signal. 19:89. PubMed
  80. Soto-Díaz K, et al. 2021. Front Immunol. 12:734349. PubMed
  81. O'Brien S, Zhang M 2015. J Immunol. 195: 695-705. PubMed
  82. Zheng J, et al. 2020. bioRxiv. . PubMed
  83. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  84. Imani J, et al. 2021. JCI Insight. 6:. PubMed
  85. Hanasoge Somasundara AV, et al. 2021. Cell Rep. 37:110099. PubMed
  86. Witkowski MT, et al. 2020. Cancer Cell. 37:867. PubMed
  87. Xu Z, et al. 2020. Cancer Immunol Res. 1354:8. PubMed
  88. Zhang C, et al. 2020. Cell Rep. 32:108206. PubMed
  89. Guldner IH, et al. 2020. Cell. 183(5):1234-1248.e25. PubMed
  90. Kräutler NJ, et al. 2020. Cell Reports. 30(4):997-1012.e6.. PubMed
  91. Flosbach M, et al. 2020. Cell Reports. 32(4):107957. PubMed
  92. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  93. Fu Z, et al. 2021. Nat Commun. 12:4462. PubMed
  94. França TT, et al. 2021. JCI Insight. 6:. PubMed
  95. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  96. Zheng J, et al. 2020. Nature. . PubMed
  97. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  98. Walsh SM, et al. 2021. eLife. 10:00. PubMed
  99. Gough D, et al. 2014. Blood. 124:2252. PubMed
  100. Liu C et al. 2019. Immunity. 51(2):381-397 . PubMed
  101. Kubota S, et al. 2019. Nat Commun. 10:1653. PubMed
  102. Yang S, et al. 2022. J Exp Med. 219:. PubMed
  103. Li J, et al. 2013. Arch Immunol Ther Exp (Warsz). 61:237. PubMed
  104. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  105. Giampazolias E, et al. 2021. Cell. . PubMed
  106. Sadik A, et al. 2020. Cell. 1252:182. PubMed
  107. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  108. Lebel MÈ, et al. 2020. Nat Commun. 3.051388889. PubMed
  109. Merlo LM, et al. 2020. Clin Pathol. 13:2632010X20951812. PubMed
  110. Wang Z, et al. 2021. Acta Pharm Sin B. 694:11. PubMed
  111. Martin MD, et al. 2020. Cell Rep. 31:107508. PubMed
  112. Burgener SS, et al. 2019. Cell Rep. 27:3646. PubMed
  113. Cianciaruso C, et al. 2020. Cell Reports. 27(10):3062-3080.e11.. PubMed
  114. Chan WY, et al. 2019. Infect Immun. 87:. PubMed
  115. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  116. Hou Y, et al. 2021. Sci Transl Med. 13:. PubMed
  117. Ye Q, et al. 2022. NPJ Vaccines. 7:84. PubMed
  118. Zhou J, et al. 2022. Int J Oncol. 61: . PubMed
  119. Wang W, et al. 2021. J Am Heart Assoc. 10:e019142. PubMed
  120. Yasuma K, et al. 2016. PLoS Pathog. 12: 1005372. PubMed
  121. Fang Y, et al. 2021. J Clin Invest. 131:00:00. PubMed
  122. Chakraborty M, et al. 2021. Cell Reports. 34(2):108609. PubMed
  123. Zhang J, et al. 2022. Biomater Res. 26:44. PubMed
  124. Jazowiecka-Rakus J, et al. 2020. Mol Ther Oncolytics. 18:335. PubMed
  125. Yokomizo-Nakano T, et al. 2020. Cancer Res. 80:2523. PubMed
  126. Shoji M, et al. 2012. PLoS One. 7:e30302. PubMed
  127. Baumann D, et al. 2020. Nat Commun. 1.969444444. PubMed
  128. Namkoong H, et al. 2018. PLoS Pathog. 14:e1006955. PubMed
  129. Sema Kurtulus et al. 2018. Immunity. 50(1):181-194 . PubMed
  130. Cantor DJ et al. 2019. Cell reports. 26(1):108-118 . PubMed
  131. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  132. Koide S, et al. 2022. iScience. 25:103603. PubMed
  133. Wu Y, et al. 2015. J Immunol. 195: 2612-2623. PubMed
  134. Tsunekuni K, et al. 2020. J Clin Med. 9:00. PubMed
  135. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
  136. Pradhan K, et al. 2021. J Immunol. 206:2980. PubMed
  137. Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed
  138. Neckermann P, et al. 2021. Front Immunol. 12:761214. PubMed
  139. Chew HY, et al. 2020. Cell. 180(5):895-914. PubMed
  140. Lavoie S, et al. 2020. Gastroenterology. 158:1359. PubMed
  141. Ajith A, et al. 2019. FASEB J. 33:5220. PubMed
  142. Luo H, et al. 2019. Cell Rep. 26:945. PubMed
  143. Oh J, et al. 2021. Clin Cancer Res. 27:4781. PubMed
  144. Li H, et al. 2022. iScience. 25:104481. PubMed
  145. Bansal K, et al. 2017. Nat Immunol. 18:263-273. PubMed
  146. Tian T, et al. 2020. Cancer Immunol Res. 660:8. PubMed
  147. Lai NY, et al. 2020. Cell. 180:33:00. PubMed
  148. Zhang B, et al. 2021. Nature. 599:471. PubMed
  149. Guo Y, et al. 2021. Nat Immunol. 22:746. PubMed
  150. Yang FM, et al. 2022. Front Immunol. 13:918241. PubMed
  151. Chow AK, et al. 2021. Cellular and Molecular Gastroenterology and Hepatology. :. PubMed
  152. Guo S, et al. 2021. Frontiers in Immunology. 11:614667. PubMed
  153. Lynn GM, et al. 2020. Nat Biotechnol. 38:320. PubMed
  154. Lucas ED, et al. 2020. Cell Reports. 33(2):108258. PubMed
  155. Lei F, et al. 2012. J Vis Exp. 63: 3986. PubMed
  156. Kubli SP, et al. 2019. Nat Commun. 10:2678. PubMed
  157. Scheyltjens I, et al. 2022. Nat Protoc. 17:2354. PubMed
  158. Yang H, et al. 2022. Viruses. 14:. PubMed
  159. Bessell CA, et al. 2020. JCI Insight. 5:. PubMed
  160. Li H, et al. 2021. Signal Transduct Target Ther. 6:389. PubMed
RRID
AB_312752 (BioLegend Cat. No. 100713)
AB_312753 (BioLegend Cat. No. 100714)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
PE/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark PLUS UV™ 395 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 3    Revision Date: 01/30/2019

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account